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For many years the antistreptolysin O (ASO) z titer has been the most com- 
monly used  immunologic indicator  of infection with  group  A  streptococci. 
Within the last decade certain limitations in using the ASO response to define 
previous streptococcal infection have been recognized. The failure to demon- 
strate an ASO response in about 20% of patients with streptococcal infection of 
the upper respiratory tract has stimulated interest in antibodies to other strep- 
tococcal antigens (1, 2). Perhaps more importantly, and certainly more provoca- 
tively, reports from this and other laboratories suggested that ASO titers were 
often not elevated or only slightly elevated in children with streptococcal pyo- 
derma when compared with children in the same or a similar population (3-5). A 
further study from this laboratory in which children were followed carefully 
with serial cultures and bleedings showed that in contrast to the antistreptococ- 
cal deoxyribonuclease B  (anti-DNase B) response, children with streptococcal 
pyoderma generally exhibited a feeble ASO response (6). This study has been 
subsequently confirmed by others (7, 8). 
Initially, several explanations for this observation seemed possible.  A gener- 
alized immunological unresponsiveness to all streptococcal extracellular anti- 
gens was ruled out by the usually excellent anti-DNase B response in patients 
with streptococcal pyoderma (6-8). The possibility that the poor ASO response 
was due to  low production of this  antigen by the pyoderma strains  seemed 
unlikely since no difference in in vitro production was demonstrated between 
strains recovered from the respiratory tract and those infecting the skin (6). 
With the failure to find support for these two possibilities, a third hypothesis 
was considered: that properties of the skin per se might be responsible for this 
peculiar disparity in the ASO response. 
It has been known for some time that cholesterol is a potent inhibitor of two of 
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the biologic properties of streptolysin O (SO), its hemolytic and its cardiotoxic 
effects (9-11). Cholesterol is found in abundance in skin (12, 13) and might exert 
an effect on SO produced during cutaneous streptococcal infections. We postu- 
lated that cholesterol and/or other related lipid compounds might also interfere 
with  its  antigenicity,  thereby  providing  an  explanation  for the  feeble  ASO 
response observed in patients with streptococcal pyoderma. 
In preliminary experiments (14), we demonstrated that chloroform:methanol 
extractable lipids from rabbit dermis and epidermis have the ability to block the 
hemolytic capacity of SO. Furthermore, these experiments suggested that such 
extracts can suppress the antigenicity of this streptococcal product. 
The additional studies reported here provide definitive confirmation of these 
findings and answers to three further questions. Firstly, do lipid extracts of skin 
have the ability to inhibit the antibody response to other streptococcal extracel- 
lular  antigens  or  is  the  suppression specific  for  SO?  Secondly,  will purified 
cholesterol,  a prominent component of these lipid extracts of skin, also specifi- 
cally inhibit the antibody response to SO? Thirdly,  are  lipid extracts of skin 
more or less effective  than similarly prepared extracts from other tissues in 
blocking the hemolytic activity of SO? 
Materials and Methods 
Preparation of Streptococcal Extracellular Antigens.  Rabbits were immunized with a  crude 
mixture of streptococcal extracellular antigens obtained from the culture supernate  of group A 
streptococcal strain C-203S  2 grown (except where otherwise noted) in Pfanstiehl broth (15) at 37°C 
for 18 h  and partially purified by ammonium sulfate precipitation,  dialysis of the redissolved 
precipitate against 10 -3 M glycine, and Millipore filtration (Millipore Corp. Bedford, Mass.) using 
methods previously described (16). The material remaining inside the dialysis bags was analyzed 
for the content of SO, streptococcal DNase, and streptococcal nicotinamide adenine dinucleotidase 
(NADase) using standard methods (6,  17,  18). 
Preparation of Lipid Extracts of Rabbit Skin and of Other Organs or Tissues.  The hair was 
shaved and the dermis and epidermis of sacrificed albino New Zealand rabbits were harvested. 
The subcutaneous adipose tissue was carefully removed. The skin was cut into small pieces, and 
lipids were extracted by adding 20 g skin to the mixing cup ofa Sorvall Omni-Mixer (Ivan Sorvall, 
Inc., Norwalk, Conn.) in the presence of a mixture of two parts chloroform and one part absolute 
methanol.  After grinding for 20  rain,  the supernate  was removed and evaporated  slowly over 
flameless heat.  The remaining lipid material was redissolved in warm absolute methanol.  The 
lipid  solution  was  poured  into  boiling  sterile  physiologic  saline  to  facilitate  removal  of the 
methanol by evaporation. The resulting lipid suspension was slowly centrifuged to remove large 
particulate matter.  At each step in the procedure, aerobic and anaerobic cultures were taken to 
confirm bacterial sterility. The final suspension appeared to be white and cloudy; there was no red 
or pink color to suggest hemoglobin. The lipid suspension  prepared from rabbit  skin contained 
approximately 0.67 mg cholesterol per ml (14). Lipids were also extracted from samples of equal 
wet weights  of the following rabbit  tissues  or organs:  ventricular myocardium,  liver,  kidney, 
spleen, and lung. After removal from the animal, the tissues were cut into small slices and washed 
many times in sterile physiologic saline until the supernate was clear and contained no visible 
blood or hemoglobin. The extraction procedure for these tissues and organs was similar to that 
described for skin.  In the hemolysis experiments,  the final concentration of suspended lipid in 
physiologic saline was that amount of lipid extracted from 0.83 g (wet weight) of tissue per ml of 
saline. 
Immunization Experiments.  The initial experiment was designed to test the effect of lipid 
extracts of rabbit  skin on the antigenicity of various streptococcal extracellular products.  Two 
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groups of albino New Zealand rabbits (15 in each group) were immunized intravenously twice 
weekly for 17 wk with a preparation of streptococcal extracellular products (see above) containing 
a sublethal dose of SO (33 U), streptococcal DNase (1,700 U), streptococcal NADase (1,100 U), and 
probably other streptococcal products of undetermined amounts. In the control group, 1 ml of the 
antigen preparation was mixed with an equal volume of physiologic saline for each injection. For 
the test group,  1 ml of the antigen preparation was mixed with an equal volume of a  saline 
suspension of lipid extract of rabbit skin. Both groups of animals were bled before immunization 
and at the 2nd, 4th, 7th, 9th, and 17th wk of immunization. At the conclusion of the experiment, 
titers of ASO, anti-DNase B, and anti-NADase were determined on all sera from each animal by 
previously described  methods (17-19). 
The protocol for the second immunization  experiment, designed to test the effects of cholesterol 
on the antigenicity  of various streptococcal  products,  was similar to that of the first experiment. 
The albino New Zealand rabbits were divided into two groups and were injected twice weekly for 9 
wk.  One group  (control)  received at the time of each injection 1.5 ml of a  partially purified 
preparation of antigens containing  similar amounts of SO and streptococcal NADase (obtained as 
described above) 3  to those used in the first experiment and mixed with 0.5 ml of  physiologic saline. 
The second group received 1.5 ml of the same partially purified antigen  preparation mixed with 0.5 
ml of a suspension of cholesterol  (greater than 99% pure; Sigma Chemical Co., St. Louis, Mo.) in 
physiologic  saline. The  saline suspension of cholesterol  was  prepared  by dissolving 100  mg 
cholesterol  in 10 ml absolute methanol and then pouring the solution into 20 cm  3 of boiling  sterile 
saline. It was found that 0.5 ml of the resulting suspension (containing 2.5 mg cholesterol)  was 
required to neutralize the hemolytic capacity of the previously determined sublethal dose (33 U) 
of SO. 
In the second immunization  experiment, the animals were bled before immunization  and at the 
3rd, 6th, and 9th wk after the beginning  of immunization. At the conclusion of the experiment, 
ASO and anti-NADase titers were simultaneously determined on all sera obtained from each 
rabbit. 
In Vitro  Inhibition of  Hemolysis Experiments.  Experiments were carried out to compare lipids 
extracted from several different rabbit organs or tissues with respect to their capacity to block 
hemolysis by SO. Lipids were extracted from rabbit skin (dermis and epidermis),  lungs, myocar- 
dium, kidney, and liver using a 2:1 mixture of chloroform and methanol as described  above. 
Suspensions of extracted lipid(s)  were diluted serially in saline (undiluted, 1:10, 1:25, 1:50, 
1:100, 1:200). 1 ml of each dilution of the various lipid suspensions was mixed with 0.5 ml of buffer 
containing 10 U of reduced SO (Difco Laboratories) for a total volume of 1.5 ml, and the mixture 
was incubated for 20 min. To each tube 0.5 ml of a washed 5% suspension of rabbit erythrocytes 
was added. After incubation again for 20 min, the tubes were centrifuged at 2,000 rpm for 2 min, 
and the  supernates were visually examined for evidence of hemolysis. For each experiment, 
appropriate SO and erythrocyte controls were run concomitantly,  i.e., one tube contained only SO 
and erythrocytes and the other tube contained only lipid extract and erythrocytes. 
Results 
Inhibition  of Antigenicity.  In  the  initial  experiment  reported  here,  the 
effects of the lipid extract of rabbit skin on the immune responses to SO, DNase 
B, and NADase were examined. One group of animals was immunized with the 
preparation of extracellular antigens  mixed  with  a  saline suspension of ex- 
tracted skin lipids, and the second group was immunized with identical amounts 
of the same preparation of antigens mixed with physiologic saline. 
Fig. 1 is a  scattergram comparing the ASO titers of sera obtained at various 
intervals from the two groups of animals. Although there was some overlap, the 
distributions of ASO titers for the two groups were different at each bleeding; 
the geometric mean ASO titer of the group immunized with antigen plus saline 
In this experiment, in which Todd-Hewitt broth (Difco Laboratories, Detroit, Mich.) was used 
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Fro.  1.  Scattergram showing the effects of skin lipid extract on ASO response in rabbits 
immunized with streptococcal extracellular products. (Geometric mean titers for each group 
are represented by horizontal bars.) On the left of each panel are shown the titers of these 
animals immunized with extracellular products mixed with saline; on the right are the 
titers of those animals immunized with the same dose of extracellular products mixed with 
lipids extracted from rabbit skin (see text). 
was significantly higher  at each interval  than  that for the group immunized 
with antigen plus lipid extract.  In contrast, for both anti-DNase B  (Fig. 2) and 
anti-NADase  (Fig.  3),  there  was  essentially  no  difference  between  the  two 
groups in the distributions of individual titers and in the geometric mean titers. 
In this experiment the most rapid rise occurred in the ASO titers. There was a 
delay in  the  rise  of anti-DNase  B  titers,  and  the  geometric mean  titers  for 
antibody to this enzyme were lower than those for ASO and anti-NADase. 
The  purpose  of  the  second  immunization  experiment  was  to  determine 
whether cholesterol is also capable of affecting the antigenicity of SO.  In one 
group the  animals  were immunized  with streptococcal extracellular  antigens 
plus saline  and  in the other group with antigens plus a  saline  suspension of 
cholesterol. 
The distribution of antibody titers and the geometric mean titers for ASO and 
anti-NADase in this experiment are shown in Figs. 4 and 5. The distribution of 
ASO titers  (Fig.  4) was generally higher,  and the geometric mean ASO titers 
were greater in rabbits immunized with the antigens mixed with saline than in 
animals  immunized with antigens mixed with cholesterol suspended in saline 
(P  <  0.05).  At  the  9-wk bleeding,  the  geometric  mean  ASO  titer  was  only 
slightly higher for the saline group; because of the death of several rabbits, the 
numbers were small and the difference was not significant (P 0.05 < P  <  0.10). 
There was no striking difference in distributions of the anti-NADase titers (Fig. 
5) for the two groups of rabbits nor was there  a  significant  difference in the 
geometric means. 
In Vitro Inhibition of Hemolysis.  In the hemolysis inhibition experiments, 
lipids extracted from several different organs or tissues were compared with 758  SUPPRESSION  OF  ANTISTREPTOLYSIN  0  RESPONSE 
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respect to their ability  to block  hemolysis  of erythrocytes by  SO.  For these 
experiments, samples of equal wet weights of each of the rabbit organs or tissues 
(skin, ventricular myocardium, lung, spleen, kidney, and liver) were extracted 
with a chloroform:methanol mixture. Suspensions of the lipid preparations were 
diluted in sterile physiologic saline and tested for their ability to block hemoly- 
sis  of rabbit erythrocytes by  a  constant  amount of SO.  The results  of these 
experiments  are  shown  in  Fig.  6.  These  photographs  are  typical  of several 
experiments with extracts prepared from each organ or tissue. 
The top left panel of Fig. 6 illustrates the results of an experiment using lipids 
extracted from rabbit dermis and epidermis. The original concentration of lipid 
extract from skin could be diluted 100-fold (1:100) before the inhibitory capacity 
of the skin lipid was sufficiently reduced to allow significant hemolysis to occur. EDWARD  L.  KAPLAN  AND  LEWIS  W.  WANNAMAKER  759 
>28- 
26- 
22- 
iv.  ~8- 
o  - 
._  ._~  14- 
0  -- 
~  I.O- 
i  -- 
02- 
Prior to 
Immunization 
o 
= 
o 
/ 30" 
o  lO  -- 
oa 
el  • 
263"  251"  oo 
oo  .~  o0o 
.o 
o= 
o 
•  So~me 
o  Choleslerol 
I 
*GEOMETRIC MEAN OF  TITER 
3  6  9 
Weeks  of Immunization  "l 
FIG.  4.  A  scattergram  showing the effect of cholesterol on the ASO responses in rabbits 
immunized with streptococcal extracellular products (see text). 
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The remaining panels are photographs of results of similar experiments using 
lipid extracts prepared in an identical manner from rabbit myocardium (heart), 
lung, liver, spleen, and kidney. In contrast to lipids extracted from skin, lipids 
extracted from each of these tissues showed no significant effect in blocking the 
hemolytic  capacity  of  SO.  Even  in  the  undiluted  preparation,  there  is  no 
evidence of inhibition by lipid extracts of heart, lung, and spleen, and there is 
only slight inhibition in the lower dilutions of extracts prepared from liver and 760  SUPPRESSION  OF  ANTISTREPTOLYSIN  O  RESPONSE 
FIG.  6.  Effects of lipid extracts of various rabbit tissues and organs on hemolysis of rabbit 
erythrocytes by SO. The results of the in vitro hemolysis tests are shown in the six panels of 
this figure.  In each panel  are  shown  eight  tubes.  Beginning on the left,  the tissue  (as 
labeled) lipid extracts are shown in the following dilutions: undiluted, 1:10, 1:25, 1:50, 1:100, 
and 1:200. The two tubes on the right of each panel are the erythrocyte and SO controls. (No 
erythrocyte buttons are visible because the supernate has been removed from the tubes with 
incomplete hemolysis to prevent further hemolysis during photography.) 
kidney. Experiments using the detergents lecithin and polyoxyethylene sorbi- 
tan monooleate (Tween 80; Fisher Scientific Co., Pittsburgh, Pa.) to make a fine 
suspension  of the  lipids  extracted from skin  did  not  significantly alter the 
results. 
Discussion 
Striking  contrasts between group A  streptococcal infections of the  throat 
(pharyngitis) and of the skin (pyoderma) have been documented in epidemiolog- 
ical studies reported in recent years (20-22). Among the most fascinating of 
these differences are those relating to the immune response (6-8) and to the 
occurrence of nonsuppurative complications  (22). The experimental findings 
reported here may bear on both of these observations. 
Analysis of the influence of the site of infection on the streptococcal antibody 
response and on the occurrence  of nonsuppurative sequelae is complicated  by the 
fact that in patients with cutaneous infections, group A streptococci may also be 
recovered from the upper respiratory tract, and these streptococci may be of the 
same M-type as those found in the skin lesions of the patient (3, 4, 23, 24). The EDWARD  L.  KAPLAN  AND  LEWIS  W.  WANNAMAKER  761 
appearance of group A streptococci of the same serological type in the upper 
respiratory tract is a late development in patients with pyoderma (25), and in 
patients in whom the infecting streptococcus is isolated from both sites, suppres- 
sion of the ASO response may be absent or less evident (6). Moreover, although 
recent studies have emphasized differences in serological types between '~skin" 
and '~throat" strains (21, 26), certain strains, notably type 49, have the capacity 
to produce clinical infection of either the upper respiratory tract or the skin (27- 
30). Studies of an outbreak of type 49  infections permitted documentation of 
differences in ASO response after recovery of streptococci from different sites 
under conditions in which strain and other variations were minimal (6). The 
strains isolated from different sites during this outbreak showed no significant 
differences  in in vitro capacity to produce SO. The findings of this epidemiologi- 
cal study suggested that it is the site of propagation per se rather than the 
infecting strain which influences the ASO response and pointed up the need to 
examine this question in the laboratory, which was the purpose of the studies 
reported here. 
This communication presents experimental evidence that (a) lipid extracts of 
rabbit skin but not other organs are effective in blocking the in vitro lysis of 
rabbit erythrocytes by SO. (b) both cholesterol and lipid extracts of skin, when 
injected intravenously with a preparation containing several different extracel- 
lular  antigens of group  A  streptococci,  significantly suppress  the  antibody 
response to SO but not to other streptococcal products. 
The inhibition of the ASO response by skin lipids  and cholesterol is only 
partial  and becomes less striking with time. Thus, in this model, all of the 
available antigen may not be bound Cantigen excess") or may not remain bound 
to lipid, or the model may involve only one of several mechanisms which may 
influence the suppression of the ASO response. However, in this regard, it is of 
interest that suppression is not always complete after natural skin infection in 
humans (6-8). 
The findings in this study support the view that the feeble ASO response 
following streptococcal pyoderma  may be due to a local factor in the skin capable 
of specifically inhibiting the antigenicity of SO. This inhibitor is present in high 
concentration in lipid extracts of rabbit skin and is most likely cholesterol which 
is known from previous studies to inhibit other biologic and toxic effects of SO 
and, as shown here, inhibits its antigenicity as well. The results of experiments 
comparing the relative ability of lipid extracts from several rabbit tissues (Fig. 
6)  to  block the  hemolytic effect of SO  are  intriguing,  but  as  yet not  fully 
explained. The excellent ability of free cholesterol to neutralize SO has been 
recognized. In fact it is thought that because most cholesterol in serum is not in 
the free state, serum itself (in the absence of antibody) is a poor inhibitor of SO 
unless the serum is contaminated by bacteria that produce an enzyme such as 
cholesterol esterase or possibly  a  proteolytic enzyme which might free the 
cholesterol or alter the spatial relationship of cholesterol in lipoprotein frag- 
ments (31). Liver, as well as others of the tissues tested, does contain cholesterol 
in  several forms,  including free cholesterol. We do  not yet have a  detailed 
chemical analysis of these tissues or data which will allow assignment of the 
relative importance of the free and bound cholesterol in these tissues in inhibit- 
ing hemolysis. Our data only indicate that when one extracts lipid from equal 762  SUPPRESSION  OF  ANTISTREPTOLYSIN  O  RESPONSE 
wet weights of these rabbit tissues, those present in skin (known to contain a 
relatively large amount of free cholesterol) appear most effective in preventing 
hemolysis of rabbit erythrocytes  by SO. Preliminary experiments searching for 
an inhibitor present in these tissues, which might interfere with the inhibitory 
effect of cholesterol and/or related lipids on hemolysis of erythrocytes by SO, 
have been suggestive but not conclusive. Additional efforts are underway in our 
laboratory. 
Cholesterol is found in abundance in human skin (12, 13). SO appears to bind 
firmly to cholesterol in vitro (32). Cholesterol has also been known for some time 
to  possess  the  capacity to  inhibit  two  of the  biologic  properties of SO:  its 
hemolytic and cardiotoxic effects. It therefore is of interest that this lipid could 
be shown to modify yet another of the biologic properties of SO, its antigenicity. 
In its effect on the antibody response, cholesterol, like the lipid extract of rabbit 
tissue, also appears to be specific for SO. This observation is of further interest 
since Fehrenbach has suggested (33) that SO and streptococcal NADase may be 
the same. Our data would not support his contention. The effect of cholesterol 
and/or other skin  lipids  in  modifying the  ASO response  and  not the  anti- 
NADase response indicates at least one significant difference. Other data from 
this laboratory also suggest that these two antigens are different (E.  D. Gray, 
personal communication), as do the studies of Shany and colleagues (34). 
The data presented in this paper raise questions regarding the mechanism(s) 
by which cholesterol and possibly other lipids which are present in abundance in 
skin modify the antigenicity of SO.  Alouf and co-workers (35, 36) have postu- 
lated the presence of two antigenic sites on the SO molecule, one of which is 
responsible for fixation of SO  to  the erythrocyte membrane, and the  other 
responsible for subsequent lysis of the cell. It has been suggested that these two 
properties of the molecule have different requirements for optimal activity (35). 
If both these sites are antigenic and result in the production of two different 
kinds of neutralizing antibody, the attachment of cholesterol and/or other lipids 
to the '~fixation site" might modify this site in such a way as to suppress its 
antigenicity but may fail to modify the antibody response to the second site. 
Preliminary studies in our laboratory, in which human sera from patients with 
streptococcal infections were repeatedly absorbed with SO preincubated with 
erythrocyte  stroma, revealed that the ASO titer can be significantly reduced but 
not eliminated. Further studies are needed to characterize the mechanism of 
inhibition of antigenicity by cholesterol and to examine critically the postulated 
existence of two antigenic sites on the SO molecule (only one of which may be 
suppressed by cholesterol) which could result in qualitative as well as quantita- 
tive differences  in the neutralizing antibodies for SO produced aider infection at 
different sites. 
The earlier epidemiological studies and the experiments reported here may 
also permit some cautious speculation about the elusive pathogenetic mecha- 
nisms involved in the development of one of the nonsuppurative sequelae of 
group  A  streptococcal infections,  rheumatic fever.  Several observations are 
perhaps relevant: first is the clinical and epidemiologic information indicating 
that, in contrast to acute poststreptecoccal nephritis which may follow either 
skin or upper respiratory tract infection, acute rheumatic fever does not follow 
streptococcal pyoderma (20); second is the known toxicity of SO for myocardial EDWARD  L.  KAPLAN  AND  LEWIS  W.  WANNAMAKER  763 
tissue  (10, 37); and  third  is  the  reported relationship of the  attack  rate  of 
rheumatic fever to the magnitude of the antibody response to this antigen (38). 
The necessity for infection with group A streptococci to occur in the upper 
respiratory tract in order for acute rheumatic fever to develop and the various 
possible explanations for this curious phenomenon have been discussed in some 
detail elsewhere (22). We shall review here only the clinical and epidemiological 
evidence supporting this observation and discuss the possibility that a  local 
inhibitor of SO  (cholesterol and/or possibly other lipids)  may play a  role in 
preventing the development of this complication in patients with impetiginous 
infection due to group A streptococci. 
For many years clinicians have made casual observations suggesting that 
infections of the skin do not lead to acute rheumatic fever. Interpretation of 
these observations has been clouded by inadequate documentation of the exact 
nature and intensity of the infectious challenge and the constancy  of  follow-up in 
such patients. Thus, uncertainties existed as to whether the streptococcus is the 
primary infecting agent  in  lesions  from which staphylococci are  often also 
recovered, whether the streptococci are regularly group A, whether they pro- 
duce M protein, whether these skin infections provoke a  significant immune 
response to streptococcal antigens, whether the streptococcus infecting the skin 
may originate from the  upper respiratory tract,  and whether unrecognized 
intervening infection may have occurred at some other site (20). 
Detailed bacteriologic, serologic, and epidemiologic studies from several dif- 
ferent laboratories have provided assurance that the primary infecting agent in 
the thick-crusted type of impetigo is a group A streptococcus which produces M 
protein, that these skin infections result in a  vigorous antibody response to 
certain streptococcal antigens other than SO and that these strains producing 
impetiginous or pyodermatous lesions of the extremities do not enter via the 
respiratory tract nor do they commonly produce signs or symptoms related to 
this site when they (in some patients) finally arrive there some weeks after the 
initiation of skin infection. Thus, the streptococci producing primary infection of 
the skin possess many of the qualities associated with streptococci infecting the 
upper respiratory tract. They also often result in repeated infections, a condition 
which may be important in the pathogenesis of acute rheumatic fever. Although 
the strains isolated in these skin infections are usually of a different serological 
type than those commonly infecting the throat (20, 21,  26,  30), no biological 
differences  have so far been detected which can account for their failure to result 
in rheumatic fever. The feeble antibody response to SO does not appear to be 
related to differences  in production of this antigen, at least as judged by in vitro 
studies (6), but rather to reflect a difference  in host response related to the site of 
infection. 
SO has been known for some years to be a cardiotoxic agent in the isolated 
perfused heart of the frog (39) and of the rabbit (40). Halbert and co-workers (10) 
have demonstrated that intravenous injection of an activated, partially purified 
preparation of  SO produces profound electrocardiographic  changes in the rabbit. 
SO also has a profound effect on beating mammalian heart cells in vitro (37). 
Thus, SO may play an essential role in damaging myocardial and other tissues 
affected by rheumatic fever, perhaps providing the initial insult, with immuno- 
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reactions (42) which result in the full-blown pathologic picture. Ginsburg (43) 
has postulated that by causing myocardial cell injury, SO may "prepare" these 
tissues for subsequent immunologic  injury by a mechanism involving one of the 
so-called "cross-reactive" antibodies. Halbert  (32) had earlier outlined an hy- 
pothesis which proposed a primary role for SO in the production of rheumatic 
fever. If SO is involved, cholesterol or other lipids in the skin might interfere by 
at least two different mechanisms: (a) inhibition of the immune response to SO 
or (b) inhibition of direct toxicity of SO (22). 
An exaggerated immune response to  SO  has been noted in  patients who 
develop rheumatic fever aider acute streptococcal pharyngitis as compared with 
patients who do not develop this complication (1, 2, 44). A similar relationship 
has  been  reported for  other streptococcal  antibodies  (45,  46),  but the  most 
extensive documentation on this point concerns the antibody response to SO. 
Indeed, in patients with streptococcal sore throat, the magnitude of the ASO rise 
correlates well with the risk of developing rheumatic fever, for both initial and 
recurrent attacks  (37,  47).  In an experimental animal model, Kirschner and 
Howie (48) have reported that the frequency and severity of heart lesions are 
related to the magnitude of the rise in ASO titer but not to the antihyaluroni- 
dase response. Therefore, it seems possible that by suppressing the ASO re- 
sponse, cholesterol or other lipids in the skin may influence the risk of develop- 
ing rheumatic fever in patients with superficial cutaneous infections (pyoderma) 
caused by group A streptococci. 
An alternative hypothesis, not involving antibody, is that local factors in the 
skin may directly affect the toxicity of SO. Cholesterol is an effective inhibitor of 
the toxic effects of SO in the intact animal (9), in the isolated perfused heart (40), 
and in beating mammalian heart cells (37). Thus, it is possible that cholesterol 
or other skin lipids may have a direct influence on the toxicity of SO by binding 
with this toxin at or near the site of its production in superficial skin lesions. 
According to this theory, the antibody response to SO would not contribute to 
the pathogenesis of rheumatic fever but would merely reflect the extent of local 
binding of this toxin. 
Further studies are needed to determine which, if either, of these two hy- 
potheses (an exaggerated antibody response or a direct toxic effect of SO) plays a 
role in the pathogenesis of rheumatic fever, and to evaluate the concept that a 
local inhibitor of SO is responsible for the odd absence of rheumatic fever after 
group A streptococcal pyoderma. 
Summary 
Lipids extracted from rabbit skin block the hemolytic capacity of SO and also 
suppress the neutralizing antibody response to this streptococcal extracellular 
antigen  in  rabbits  immunized intravenously.  The  modification in  antibody 
response is specific for SO; the antibody responses to streptococcal DNase B and 
to streptococcal NADase are not affected. Cholesterol, a lipid present in abund- 
ance in skin, has a similar specific effect on the antigenicity of SO and may be 
the component responsible for the demonstrated effects of these lipid extracts of 
skin.  In vitro experiments indicate that lipid extracts of rabbit skin have a 
greater capacity to block the hemolytic capacity of SO than do lipid extracts of 
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These data support the view that the feeble ASO response observed in patients 
with streptococcal pyoderma is a  result of the abundance of a  local lipid inhibi- 
tor, such as cholesterol, in the skin. They may also bear on the pathogenesis of 
rheumatic  fever,  a  complication  which  apparently  does  not  occur following 
group A streptococcal pyoderma. Two possible explanations for this remarkable 
epidemiologic observation, both related to the presence of a  local inhibitor, are 
considered: (a)  suppression of the ASO response,  the magnitude of which has 
been correlated with the risk of developing rheumatic fever aider streptococcal 
infection of the throat, and (b) inhibition of the toxicity of SO, which has been 
shown to have a  direct toxic effect on the  mammalian  heart and on isolated 
beating myocytes. 
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